Skip to main content
HairCited

Spironolactone para Pérdida Capilar de Patrón Femenino

A

Basado en 19 estudios (2 meta-analyses, 4 RCTs) con 5,743 participantes en total. 16/19 estudios muestran efectos positivos.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'ingredient\u003Dspironolactone\u0026condition\u003Dfemale\u002Dpattern\u002Dhair\u002Dloss'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

Conclusión

Spironolactone is strongly supported by research as an effective option that may help women with female pattern hair loss, with both oral and topical formulations showing benefits in clinical trials.

  • 84% of studies show positive effects, including 4 RCTs focused on women
  • Both oral and topical formulations have demonstrated benefits
  • A dedicated meta-analysis confirms efficacy and safety in female pattern hair loss
  • Combination with minoxidil may offer enhanced results

Key Study Findings

Review
Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments.
Dose: None vs: None Outcome: None Efecto: None None

Población: women with androgenetic alopecia (female pattern hair loss)

Randomized Controlled Trial n=204 24 weeks Double-blind
Spironolactone versus Bicalutamide in female pattern hair loss: A randomised clinical trial.
Dose: Bicalutamide 50 mg/day; spironolactone 100 mg/day vs: Spironolactone 100 mg/day Outcome: Hair density and shaft diameter change at 24 … Efecto: Frontal: +5.05 vs +3.13 hairs/cm2 (diff 1.92) P < 0.001 (frontal); P = 0.028

Población: Women 18-50 with Sinclair Grade II-V FPHL (India)

randomized controlled trial n=80 24 weeks Single-blind
Evaluation of the Efficacy and Safety of Topical Spironolactone versus Topical Minoxidil in the Treatment …
Dose: Group A: 1% topical spironolactone gel twice daily; Group B: 5% topical minoxidil gel twice daily vs: Placebo Efecto: Both groups showed statistically significant improvement. Group A: 10 mild, 16 moderate, 2 excellent None
RCT n=48 24 weeks Double-blind
Efficacy and safety of oral spironolactone for female pattern hair loss in premenopausal women: a …
Dose: Spironolactone 100 mg once daily vs: Placebo Efecto: Terminal hair counts: 9.48 vs 5.32 hairs/cm2; hair diameter: 4.23 vs 2.96 μm; moderate-to-marked imp p=0.063 (terminal hair counts)
Randomized Controlled Trial n=240 520 weeks Open-label
Nutritional deficiencies after sleeve gastrectomy and Roux-en-Y gastric bypass at 10 years: secondary analysis of …
Dose: None vs: Laparoscopic Roux-en-Y gastric bypass (LRYGB) Outcome: Nutritional deficiency prevalence at 10 years Efecto: Iron deficiency: LSG 14% vs LRYGB 41% p=0.017 (iron deficiency)

Población: Severely obese adults undergoing bariatric surgery

Review
Male and female pattern hair loss.
Dose: None vs: Placebo Efecto: None None

Key Statistics

45

Estudios

6441

Participantes

Positive

A

Calificación

Referenced Papers

Australian prescriber 2025 2 citas
Journal of cosmetic … 2023 3 citas
Clinical and experimental … 2020 20 citas
Australian journal of … 2018 8 citas
The Cochrane database … 2016 18 citas
Clinical obstetrics and … 2015 9 citas
Current problems in … 2015 8 citas
International journal of … 2013
Skinmed 2010 33 citas
Seminars in cutaneous … 2009 4 citas
Duodecim; laaketieteellinen aikakauskirja 2006
The British journal … 2005 205 citas
Journal of the … 2005 64 citas

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Dosificaciones de uso común

hairloss:
100-200 mg/day (prescription)

Límite superior: 200 mg/day (hair loss indication)

Dosificaciones estudiadas en la investigación

Dosificación Duración Efecto N
None -- Neutral --
Bicalutamide 50 mg/day; spironolactone 100 mg/day 24 weeks Positive 204
Group A: 1% topical spironolactone gel twice daily; Group B: 5% topical minoxidil gel twice daily 24 weeks Positive 80
Spironolactone 100 mg once daily 24 weeks Positive 48
None 520 weeks Positive 240
None -- Positive --
Group A: topical finasteride 1% solution; Group B: topical spironolactone 5% solution; Group C: topi 16 weeks Positive 45
4 g -- Neutral --

Mejor momento para tomar: Once or twice daily with food; prescription required

Safety & Side Effects

Efectos secundarios reportados

  • Menstrual irregularities
  • Breast tenderness
  • Hyperkalemia (elevated potassium levels)
  • Dizziness and orthostatic hypotension
  • Frequent urination

Interacciones conocidas

  • ACE inhibitors and ARBs (increased hyperkalemia risk)
  • Potassium supplements and potassium-sparing diuretics (dangerous hyperkalemia)
  • NSAIDs (may reduce diuretic effectiveness and increase kidney risk)
  • Digoxin (spironolactone may increase digoxin levels)

Ingesta máxima tolerable: 200 mg/day (hair loss indication)

Consulte siempre a su profesional de salud antes de comenzar cualquier suplemento.Siempre consulte a su profesional de salud antes de comenzar cualquier suplemento.

Frequently Asked Questions

Does Spironolactone help with Pérdida Capilar de Patrón Femenino?
Based on 45 studies with 6,441 participants, there is strong evidence from multiple clinical trials that Spironolactone may support Pérdida Capilar de Patrón Femenino management. Our evidence grade is A (Strong Evidence).
How much Spironolactone should I take for Pérdida Capilar de Patrón Femenino?
Studies have used various dosages. A commonly studied range is 100-200 mg/day (prescription). Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Spironolactone?
Reported side effects may include Menstrual irregularities, Breast tenderness, Hyperkalemia (elevated potassium levels), Dizziness and orthostatic hypotension. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Spironolactone and Pérdida Capilar de Patrón Femenino?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 45 peer-reviewed studies with 6,441 total participants. The overall direction of effect is positive.

Related Evidence

Spironolactone para otras condiciones

Aviso legal FDA: Estas declaraciones no han sido evaluadas por la Food and Drug Administration. Los productos y la información en este sitio web no están destinados a diagnosticar, tratar, curar ni prevenir ninguna enfermedad. Las calificaciones de evidencia presentadas se basan en nuestro análisis de investigación publicada revisada por pares y no constituyen consejo médico. Siempre consulte a su profesional de salud antes de comenzar cualquier régimen de suplementos.